Fengshen Kuo

9.7k total citations · 1 hit paper
56 papers, 2.4k citations indexed

About

Fengshen Kuo is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Fengshen Kuo has authored 56 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 23 papers in Molecular Biology and 18 papers in Oncology. Recurrent topics in Fengshen Kuo's work include Renal cell carcinoma treatment (16 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Ferroptosis and cancer prognosis (9 papers). Fengshen Kuo is often cited by papers focused on Renal cell carcinoma treatment (16 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Ferroptosis and cancer prognosis (9 papers). Fengshen Kuo collaborates with scholars based in United States, Germany and Israel. Fengshen Kuo's co-authors include Timothy A. Chan, Nadeem Riaz, Luc G.T. Morris, Diego Chowell, A. Ari Hakimi, Vladimir Makarov, Naiyer A. Rizvi, Ruhong Zhou, Sviatoslav M. Kendall and Benjamin D. Greenbaum and has published in prestigious journals such as Nature, Science and Nature Medicine.

In The Last Decade

Fengshen Kuo

52 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

2017 738 citations Diego Chowell, Luc G.T. Morris et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fengshen Kuo United States	19	1.3k	819	789	770	519	56	2.4k
Jaemoon Koh South Korea	29	1.5k 1.1×	600 0.7×	687 0.9×	1.0k 1.4×	351 0.7×	93	2.6k
Audrey Lupo France	20	1.7k 1.2×	597 0.7×	1.5k 1.8×	693 0.9×	322 0.6×	44	2.8k
Sangeeta Goswami United States	19	1.2k 0.9×	801 1.0×	1.2k 1.6×	626 0.8×	314 0.6×	57	2.7k
Evgeny Yakirevich United States	28	846 0.6×	833 1.0×	399 0.5×	614 0.8×	540 1.0×	89	2.3k
An Na Seo South Korea	27	1.4k 1.1×	803 1.0×	417 0.5×	681 0.9×	555 1.1×	107	2.5k
Simone Reu Germany	20	1.2k 0.9×	826 1.0×	285 0.4×	596 0.8×	394 0.8×	53	2.2k
Jérémy Goc France	23	2.4k 1.8×	669 0.8×	2.5k 3.2×	745 1.0×	361 0.7×	28	3.9k
Haijun Deng China	25	994 0.7×	730 0.9×	299 0.4×	659 0.9×	611 1.2×	72	2.1k
Jishu Wei China	27	1.1k 0.8×	904 1.1×	418 0.5×	304 0.4×	654 1.3×	99	2.0k
Max D. Wellenstein Netherlands	9	1.3k 0.9×	691 0.8×	1.3k 1.6×	307 0.4×	394 0.8×	10	2.3k

Countries citing papers authored by Fengshen Kuo

Since Specialization

Citations

This map shows the geographic impact of Fengshen Kuo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengshen Kuo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengshen Kuo more than expected).

Fields of papers citing papers by Fengshen Kuo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengshen Kuo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengshen Kuo. The network helps show where Fengshen Kuo may publish in the future.

Co-authorship network of co-authors of Fengshen Kuo

This figure shows the co-authorship network connecting the top 25 collaborators of Fengshen Kuo. A scholar is included among the top collaborators of Fengshen Kuo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengshen Kuo. Fengshen Kuo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eismann, Lennert, Amy Xie, Cerise Tang, et al.. (2024). Sample Site Impacts RNA Biomarkers for Renal Cell Carcinoma. European Urology. 87(1). 79–83. 2 indexed citations

Khaleel, Sari, Marlon Perera, Nathan Papa, et al.. (2024). Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors. Urologic Oncology Seminars and Original Investigations. 43(3). 192.e21–192.e28. 2 indexed citations

Gao, Sizhi Paul, Fengshen Kuo, Florestan Koll, et al.. (2024). Abstract 4632: Lineage plasticity as a determinant of antibody-drug conjugate target expression in urothelial bladder cancer. Cancer Research. 84(6_Supplement). 4632–4632. 3 indexed citations

Gebrael, Georges, Hao Wang, Michael A. Carducci, et al.. (2023). 2023 Kidney Cancer Research Summit Abstracts. The Oncologist. 28(Supplement_1). S1–S1. 1 indexed citations

Benedetti, Elisa, Eric Minwei Liu, Cerise Tang, et al.. (2023). A multimodal atlas of tumour metabolism reveals the architecture of gene–metabolite covariation. Nature Metabolism. 5(6). 1029–1044. 27 indexed citations

Kotecha, Ritesh R., Andrea Knežević, Kanika Arora, et al.. (2023). Genomic ancestry in kidney cancer: Correlations with clinical and molecular features. Cancer. 130(5). 692–701. 5 indexed citations

Tang, Cerise, Amy Xie, Eric Minwei Liu, et al.. (2023). Immunometabolic coevolution defines unique microenvironmental niches in ccRCC. Cell Metabolism. 35(8). 1424–1440.e5. 14 indexed citations

Ged, Yasser, Alejandro Sánchez, Sujata Patil, et al.. (2022). Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade. Clinical Cancer Research. 28(23). 5180–5189. 20 indexed citations

Humtsoe, Joseph O., et al.. (2022). Development and Characterization of MYB-NFIB Fusion Expression in Adenoid Cystic Carcinoma. Cancers. 14(9). 2263–2263. 11 indexed citations

10.

Kansler, Emily R., Saïda Dadi, Chirag Krishna, et al.. (2022). Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies. Nature Immunology. 23(6). 904–915. 55 indexed citations

11.

Dong, Yiyu, Yongxing Gong, Fengshen Kuo, et al.. (2021). Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity. Molecular Cancer Therapeutics. 21(2). 382–394. 4 indexed citations

12.

Zhang, Minggang, Zeguo Zhao, Yuri Pritykin, et al.. (2021). Ectopic activation of the miR-200c–EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy. Science Translational Medicine. 13(611). eabg4328–eabg4328. 9 indexed citations

13.

Korczeniewska, Olga A., Fengshen Kuo, Ching‐Yu Huang, et al.. (2021). Genetic variation in catechol‐O‐methyltransferase is associated with individual differences in conditioned pain modulation in healthy subjects. The Journal of Gene Medicine. 23(11). e3374–e3374. 9 indexed citations

14.

Linxweiler, Maximilian, Fengshen Kuo, Nora Katabi, et al.. (2020). The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. Clinical Cancer Research. 26(12). 2859–2870. 79 indexed citations

15.

Scarpa, Joseph R., Renzo G. DiNatale, Roy Mano, et al.. (2020). Identifying Clear Cell Renal Cell Carcinoma Coexpression Networks Associated with Opioid Signaling and Survival. Cancer Research. 81(4). 1101–1110. 12 indexed citations

16.

Hakimi, A. Ari, Kyrollis Attalla, Renzo G. DiNatale, et al.. (2020). A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nature Communications. 11(1). 4168–4168. 44 indexed citations

17.

Hakimi, A. Ari, Martin H. Voss, Fengshen Kuo, et al.. (2019). Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer Discovery. 9(4). 510–525. 156 indexed citations

18.

Sánchez, Alejandro, Helena Furberg, Fengshen Kuo, et al.. (2019). Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. The Lancet Oncology. 21(2). 283–293. 127 indexed citations

19.

Voss, Martin H., Albert Reising, Yuan Cheng, et al.. (2018). Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. The Lancet Oncology. 19(12). 1688–1698. 107 indexed citations

20.

Chowell, Diego, Luc G.T. Morris, Claud Grigg, et al.. (2017). Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 359(6375). 582–587. 738 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact